These findings, along with ours, strengthen the importance of suggesting concomitantTP53 p.R337H genetic testing for women affected by breast cancer beforeage 45, irrespective of family history, particularly in the South and Southeast of Brazil,where the prevalence of a germline TP53 is considerably higher thanelsewhere in the world. The gene discussed is TP53; the disease is breast carcinoma.